Table 3.
Univariable and multivariable analysis of duration of pemetrexed treatment.
| Variable | Univariable analysis | Multivariable analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |||
| Lower | Upper | Lower | Upper | |||||
| Age (≥65 vs. <65 years) | 1.045 | 0.896 | 1.219 | 0.574 | - | - | - | - |
| Sex (female vs. male) | 0.889 | 0.772 | 1.022 | 0.099 | - | - | - | 0.642 |
| Smoking status (smoker vs. non-smoker) | 1.163 | 1.011 | 1.338 | 0.034 | 1.167 | 1.015 | 1.342 | 0.031 |
| ECOG PS (2 vs. 0–1) | 2.105 | 1.626 | 2.726 | <0.001 | 2.112 | 1.631 | 2.735 | <0.001 |
| EGFR Mutation | ||||||||
| (+ vs. -) | 1.071 | 0.909 | 1.261 | 0.413 | - | - | - | - |
| (unknown vs. -) | 0.976 | 0.814 | 1.171 | 0.795 | - | - | - | - |
| ALK Rearrangement | ||||||||
| (+ vs. -) | 0.716 | 0.520 | 0.987 | 0.041 | - | - | - | 0.056 |
| (unknown vs. -) | 1.000 | 0.866 | 1.155 | 0.996 | - | - | - | 0.943 |
| KRAS Mutation | ||||||||
| (+ vs. -) | 1.754 | 0.919 | 3.348 | 0.088 | - | - | - | 0.117 |
| (unknown vs. -) | 1.069 | 0.878 | 1.301 | 0.509 | - | - | - | 0.788 |
| ROS1 Fusion | ||||||||
| (+ vs. -) | 0.604 | 0.343 | 1.063 | 0.080 | - | - | - | 0.096 |
| (unknown vs. -) | 1.010 | 0.855 | 1.192 | 0.911 | - | - | - | 0.762 |
HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status.